[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome

Objective: To investigate the controversy that still exists regarding the time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A (BOTOX) in patients with neurogenic and non-neurogenic overactive bladder syndrome (OAB), as intra-detrusor injection of botulinum to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Awad Thahir, Rawan Al Yousef, Mishari AlMutairi, Ahmad El-Nahas, Abdulateef Al-Terki, Tariq Al-Shaiji
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2018
Materias:	Diseases of the genitourinary system. Urology RC870-923
Acceso en línea:	https://doaj.org/article/d9a3dcb3d3cc46359b7a23e71100cf02
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d9a3dcb3d3cc46359b7a23e71100cf02
record_format	dspace
spelling	oai:doaj.org-article:d9a3dcb3d3cc46359b7a23e71100cf022021-12-02T12:07:16Z[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome2090-598X10.1016/j.aju.2018.10.076https://doaj.org/article/d9a3dcb3d3cc46359b7a23e71100cf022018-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2090598X18301700https://doaj.org/toc/2090-598XObjective: To investigate the controversy that still exists regarding the time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A (BOTOX) in patients with neurogenic and non-neurogenic overactive bladder syndrome (OAB), as intra-detrusor injection of botulinum toxin has emerged as a second-line option for patients with neurogenic and non-neurogenic OAB who are refractory to first-line treatment modalities. Methods: This is a retrospective study of 71 patients, who underwent intra-detrusor injection of botulinum toxin A from December 2012 to December 2017. All procedures were performed in a single institute by the same surgeon. Data analysed included patient demographics, disease specifics, and outcomes of the procedure. Results: The mean (range) age of the 71 patients was 44 (14–75) years, 48 of which were females (68%). In all, 58% of the patients had neurogenic bladder and 42% had non-neurogenic bladder. Metabolic syndrome was identified in 36 patients (50%) and 24 (34%) had neurological deficits. The neurogenic bladder group received 200 U of BOTOX, whereas the rest received 100 U. The median response time to BOTOX injection was 7 days and this was used as a threshold: Group 1 was early response (⩽7 days) and Group 2 late response (>7 days). This was utilised to analyse the effect of certain variables on response time. Age, gender, smoking status and underlying pathology had no significant effect on response time with P values of 0.14, 0.95, 0.71 and 0.7, respectively. Only diabetes and type of incontinence (wet vs dry) played a significant role with regards to response time with P values of 0.004 and 0.009, respectively. Conclusion: The median time of onset after intradetrusor BOTOX injection was found to be 7 days. Only diabetes and type of incontinence significantly affected the response time to BOTOX injection. A larger sample size and a prospective analysis of data are warranted to verify and validate these findings.Awad ThahirRawan Al YousefMishari AlMutairiAhmad El-NahasAbdulateef Al-TerkiTariq Al-ShaijiTaylor & Francis GrouparticleDiseases of the genitourinary system. UrologyRC870-923ENArab Journal of Urology, Vol 16, Iss , Pp S14-S15 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the genitourinary system. Urology RC870-923
spellingShingle	Diseases of the genitourinary system. Urology RC870-923 Awad Thahir Rawan Al Yousef Mishari AlMutairi Ahmad El-Nahas Abdulateef Al-Terki Tariq Al-Shaiji [29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome
description	Objective: To investigate the controversy that still exists regarding the time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A (BOTOX) in patients with neurogenic and non-neurogenic overactive bladder syndrome (OAB), as intra-detrusor injection of botulinum toxin has emerged as a second-line option for patients with neurogenic and non-neurogenic OAB who are refractory to first-line treatment modalities. Methods: This is a retrospective study of 71 patients, who underwent intra-detrusor injection of botulinum toxin A from December 2012 to December 2017. All procedures were performed in a single institute by the same surgeon. Data analysed included patient demographics, disease specifics, and outcomes of the procedure. Results: The mean (range) age of the 71 patients was 44 (14–75) years, 48 of which were females (68%). In all, 58% of the patients had neurogenic bladder and 42% had non-neurogenic bladder. Metabolic syndrome was identified in 36 patients (50%) and 24 (34%) had neurological deficits. The neurogenic bladder group received 200 U of BOTOX, whereas the rest received 100 U. The median response time to BOTOX injection was 7 days and this was used as a threshold: Group 1 was early response (⩽7 days) and Group 2 late response (>7 days). This was utilised to analyse the effect of certain variables on response time. Age, gender, smoking status and underlying pathology had no significant effect on response time with P values of 0.14, 0.95, 0.71 and 0.7, respectively. Only diabetes and type of incontinence (wet vs dry) played a significant role with regards to response time with P values of 0.004 and 0.009, respectively. Conclusion: The median time of onset after intradetrusor BOTOX injection was found to be 7 days. Only diabetes and type of incontinence significantly affected the response time to BOTOX injection. A larger sample size and a prospective analysis of data are warranted to verify and validate these findings.
format	article
author	Awad Thahir Rawan Al Yousef Mishari AlMutairi Ahmad El-Nahas Abdulateef Al-Terki Tariq Al-Shaiji
author_facet	Awad Thahir Rawan Al Yousef Mishari AlMutairi Ahmad El-Nahas Abdulateef Al-Terki Tariq Al-Shaiji
author_sort	Awad Thahir
title	[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome
title_short	[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome
title_full	[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome
title_fullStr	[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome
title_full_unstemmed	[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome
title_sort	[29] time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin a in patients with neurogenic and non-neurogenic overactive bladder syndrome
publisher	Taylor & Francis Group
publishDate	2018
url	https://doaj.org/article/d9a3dcb3d3cc46359b7a23e71100cf02
work_keys_str_mv	AT awadthahir 29timeofonsetofsymptomreliefafterintraoperativedetrusorinjectionofbotulinumtoxinainpatientswithneurogenicandnonneurogenicoveractivebladdersyndrome AT rawanalyousef 29timeofonsetofsymptomreliefafterintraoperativedetrusorinjectionofbotulinumtoxinainpatientswithneurogenicandnonneurogenicoveractivebladdersyndrome AT misharialmutairi 29timeofonsetofsymptomreliefafterintraoperativedetrusorinjectionofbotulinumtoxinainpatientswithneurogenicandnonneurogenicoveractivebladdersyndrome AT ahmadelnahas 29timeofonsetofsymptomreliefafterintraoperativedetrusorinjectionofbotulinumtoxinainpatientswithneurogenicandnonneurogenicoveractivebladdersyndrome AT abdulateefalterki 29timeofonsetofsymptomreliefafterintraoperativedetrusorinjectionofbotulinumtoxinainpatientswithneurogenicandnonneurogenicoveractivebladdersyndrome AT tariqalshaiji 29timeofonsetofsymptomreliefafterintraoperativedetrusorinjectionofbotulinumtoxinainpatientswithneurogenicandnonneurogenicoveractivebladdersyndrome
_version_	1718394719370739712

[29] Time of onset of symptom relief after intraoperative detrusor injection of botulinum toxin A in patients with neurogenic and non-neurogenic overactive bladder syndrome

Ejemplares similares